Background: There is considerable interest in therapeutic application of intranasal oxytocin in psychiatric disorders, but while clinical trials typically use daily dosing protocols it has not been established whether this is optimal or if there are moderating influences of oxytocin receptor genotype.
Introduction
Intranasal oxytocin (OT) has been proposed as a potential therapy for social dysfunction in psychiatric disorders in relation to autism spectrum disorder, schizophrenia and social anxiety [1] [2] [3] as well as in the context of fear-extinction [4] and as an adjunct to the placebo effect for working memory deficits [5] . To date the functional effects of intranasal OT administration have been based primarily on a single dose and there is evidence that a 24IU dose may be optimal [6] . However, initial clinical trials reporting some therapeutic efficacy have typically used twice-daily treatment protocols lasting a number of weeks [1, [7] [8] [9] [10] [11] , even though no studies have investigated if this is an optimal strategy. This is an important issue since clinical trials to date have reported relatively modest or inconsistent effects of chronic daily intranasal OT treatment and there is evidence from animal studies for rapid desensitization of OT receptors in some brain regions [12] , most notably in the amygdala which mediates many of OTs functional effects on social cognition and anxiety [1] . Rodent models have reported that in contrast to single doses, chronic administration of OT can actually produce social impairment [13] [14] [15] and reduced receptor expression in the amygdala and nucleus accumbens [15] . Furthermore, chronic versus single administration of OT can produce differential neurochemical changes in both the rodent and human frontal cortex [16] .
Different OT receptor (OXTR) genotypes have been associated with social behaviors and may also influence sensitivity of behavioral and neural responses to intranasal OT. In particular, OXTR polymorphisms rs53576 and rs2254298 have been associated with autism [17] , deficits in social and emotional processing including empathy [18] [19] [20] and individual variations in behavioral and neural responses to intranasal OT [21, 22] . Variants of rs2254298 may also be a more general biomarker for social dysfunction across a number of psychiatric disorders [23] .
While single doses of OT have been reported to produce numerous functional effects two have emerged as promising candidate neural biomarkers: reduced amygdala responses to fear faces and increased resting state functional connectivity between the amygdala and medial prefrontal cortex [1, 6] . Both biomarkers may be particularly relevant in the context of anxiety in terms of reduced responses to social threat and enhanced top-down control of emotion [24] , although OT effects on the amygdala are important for a range of social cognition functions [1] [2] [3] 6 ]. In the current pre-registered neuroimaging study we therefore conducted a double-blind, randomized between subject placebo (PLC)-controlled design experiment including 138 adult male subjects to investigate the effects of acute (single dose) and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on these two biomarkers and valence, arousal and intensity ratings of fear faces. Additionally, we assessed the influence of OXTR rs53576 and rs2254298 polymorphisms on the acute and repeated dose effects of intranasal OT and associations with trait autism [25] .
Material and Methods
Participants. A total of 147 healthy, right-handed healthy adult male subjects were enrolled according to common inclusion and exclusion criteria for human OT-administration studies. This subject number achieves >90% power for a medium effect size of 0.45. A total of 9 subjects were excluded due to failure to complete the study or excessive head movement (see Fig 1) . Subjects were randomly assigned to repeated intranasal treatment (single daily dose on five consecutive days) of (1) placebo (PLC; n = 46, M ± SD, 22.46± 2.3 years), (2) oxytocin (OT5; n = 49, M ± SD, 21.78 ± 2.3 years), or interleaved OT and PLC (OT on days 1, 3, 5, PLC on days 2, 4; OT3; n = 43, M ± SD, 21.02 ± 2.0 years) (see SI). To ensure compliance all subjects were required to come to the center every day and supervised during self-administration of nasal sprays. To control for between-group differences in potential confounders pre-treatment levels of anxiety, depression, and empathy were assessed using validated scales. Measures of trait autism were assessed using the AQ [25] . There were no significant differences between the OT and PLC groups ( Table   S4 ). The study was approved by the local ethics committee (Institutional Review Board, University of Electronic Science and Technology of China) and subjects provided written informed consent. The study was in accordance with the latest revision of the Declaration of Helsinki, pre-registered at Clinical Trials.gov (NCT03610919) and in line with recommendations for trials in psychological experiments [26] (see Fig. 1 for Consort flow diagram). Subjects received monetary compensation for participation.
Experimental procedures.
The study employed a double-blind, randomized, placebo-controlled, between-subject design. The OT and PLC sprays used in the 3 groups were both supplied by Sichuan Meike Pharmaceutical Co. Ltd, Sichuan, China in identical dispenser bottles containing identical ingredients (glycerine and sodium chloride) other than OT. In line with recommended guidelines experiments started 45 minutes after intranasal administration [27] . In post-treatment interviews collected on days 1 and 5 subjects were unable to identify better than chance whether they had received OT or PLC (χ 2 < 0.1, ps > 0.2, Table S5 ) confirming successful blinding over the entire study period.
For OXTR genotyping subjects provided buccal swaps on the 1 st day for analysis of OXTR rs2254298, rs53576 SNPs (see SI and [28] ).
For the implicit face-emotion processing task 208 grayscale facial stimuli displaying happy, neutral, angry or fearful facial expressions (n = 26 per category, 50% female) were used. Stimuli were initially rated with respect to arousal and valence by an independent group of subjects and two matched independent sets of stimuli were produced for use on the 1 st and 5 th days (all ps > 0.3, see SI for details and Table S6 ). The presentation order of the two sets was counter balanced. To ensure attentive processing subjects were required to identify the gender of each face picture (see Figure S2 ).
Primary outcomes and analysis plan.
Face emotion-related amygdala responses were assessed using the event-related implicit face processing fMRI paradigm on treatment days 1 and 5. Intrinsic amygdala connectivity was assessed by means of two resting state fMRI assessments (before and after the task-paradigm). Valence, arousal and intensity ratings (scale: 1-9) for the facial stimuli were collected immediately after MRI acquisition as additional behavioral outcomes (further details see SI). In line with the main aim of the study changes in amygdala fear reactivity and amygdala intrinsic connectivity between the 1 st and 5 th day served as primary outcome measures. Changes in valence, arousal and intensity ratings for the fear faces represented an associated behavioral outcome measure.
Imaging acquisition and analysis.
MRI data was acquired using standard sequences on a 3T GE MR750 system. In addition to the functional time series high resolution T1-weighted structural MRI data was acquired at both time points to improve normalization and control for acute and chronic effects of treatment on brain structure. MRI data was preprocessed using validated procedures in SPM12 [29] (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm) and Data Processing Assistant or Resting-State fMRI [30] (DPARSFA; http://rfmri.org/DPARSF) (for details see SI). First level General Linear Models (GLM) for the task-related fMRI data included separate regressors for the four emotional conditions, gender identity rating period and 6 movement parameters and appropriate contrasts were subjected to a second level random effects analysis.
Analysis strategy
To identify OT-sensitive regions and confirm previous findings on suppression of amygdala reactivity following single-dose OT-administration[2] a voxel-wise whole-brain two-sample t-test was conducted in SPM comparing neural activity in OT-and PLC-treated subjects on the1 st day. For all subsequent analyses a 6-mm sphere centered at the maximum t-values of the acute OT effects in the amygdala served as target region to determine different trajectories of amygdala functioning following acute versus repeated treatment (for similar approach see [6] ).
Primary outcomes: amygdala fear-reactivity and intrinsic connectivity.
Differences in stimulus-induced amygdala fear reactivity were examined by means of mixed ANOVAs with treatment (PLC, OT3, OT5) as between-subject factor, time point (1 st day, acute effects; 5 th day, chronic effects) as within-subject factor and extracted target region amygdala-reactivity towards fearful faces as dependent variable (parameter estimates extracted using Marsbar, http://marsbar.sourceforge.net) followed by appropriate Bonferroni-corrected post-hoc comparisons.
Differences in amygdala connectivity were determined using a voxel-wise seed-to-whole-brain ANOVA as implemented in the SPM flexible factorial design with treatment (PLC, OT3, OT5) as between-subject factor, time point (1 st day, acute effects; 5 th day, chronic effects) as within-subject factor and amygdala connectivity maps as dependent variable. To account for potential effects of task-engagement on intrinsic amygdala connectivity the primary analysis focused on pre-task resting state maps. A subsequent ROI analyses on the post-task data (focusing on extracted estimates from a 6mm sphere centered at vmPFC determined by the pre-task data) served as a replication and further validation.
Secondary outcome measures: OXTR genotype and trait autism associations.
For rs2254298 subjects were divided into A+ carriers (AA and AG) and Anon-carriers (GG) and rs53576 into G+ carriers (GG and GA) and G-non-carriers (AA). To explore effects of genotype as a secondary outcome measure, OXTR group was included as additional between-subject factor in the corresponding ANOVAs and amygdala fear reactivity, amygdala-vmPFC intrinsic functional connectivity and behavior rating response served as dependent variables. Associations between neural and behavioral effects of OT and trait autism were carried out by analyzing correlations with AQ scores.
Control for treatment effects on brain structure.
To control for potential confounding effects of single-and repeated OT-administration brain structure, a voxel-based morphometry (VBM) analysis was conducted on the T1-weighted images acquired on both testing days using SPM12 standard procedures [31, 32] . Effects of single-and repeated dose administration were explored concordant with the fMRI analyses (see SI).
Thresholding and statistical implementation.
Voxel-wise whole brain analyses in SPM were thresholded at a cluster-based 
Results

Acute effects of OT on neural responses to emotional faces
In accordance with the primary outcome measure of the trial analyses focused on the neural responses to fearful faces, however no significant effects of OT were found for happy or angry faces. Comparison of single-dose OT-and PLC-treated subjects (1 st day) revealed significantly decreased right amygdala reactivity towards fearful faces on the whole brain level (k = 78, pFWE = 0.043, x=27, y=-4, z=-13) ( Fig.2A ).
Cytoarchitectonic probabilistic localization (Anatomy toolbox V1.8 [35] ) mapped the peak coordinate with >80% probability to the basolateral amygdala sub-region. In addition, OT also decreased fear-reactivity in the right superior frontal gyrus and bilateral primary visual cortex (see SI and Table S1 ). There were no significant differences between the OT3 and OT5 groups on the 1 st day.
Primary outcome measures: effects of repeated doses on OT-evoked changes
Mixed ANOVAs with treatment (PLC, OT3, OT5) and time point (1 st day, acute effects; 5 th day, chronic effects) as factors and right amygdala fear reactivity as dependent variable revealed a significant main effect of treatment (F2, 135 = 7.854, p = 0.001, η 2 p = 0.104) and a treatment x time point interaction (F2, 135 = 5.737, p = 0.004, η 2 p =0.078). Post-hoc Bonferroni corrected comparisons between groups on the 5 th day revealed that the OT3 group exhibited a suppression of right amygdala fear reactivity relative to both the PLC (p = 0.001, Cohen's d = 0.70) and OT5 groups (p = 0.018, d = 0.52) but the OT5 group did not (p = 0.266, d = 0.24, relative to the PLC group). Within group comparisons revealed that whereas amygdala reactivity did not change on day 1 relative to day 5 in the PLC group (p = 0.090, d = 0.29), its suppression was significantly enhanced in the OT3 group (p = 0.019, d = 0.40) and attenuated in the OT5 one (p = 0.044, d = 0.38) ( Fig. 2B) .
For the behavioral ratings mixed ANOVAs with treatment and time point as within-subject factors revealed a significant main effect of treatment for arousal, but not intensity ratings (F1, 135 = 3.56, p = 0.031, η 2 p = 0.05, intensity: F1, 135 = 1.24, p = 0.292, η 2 p = 0.018), and time point for both emotional arousal and intensity ratings (arousal: F1, 135 = 12.59, p = 0.001, η 2 p = 0.085, intensity: F1, 135 = 13.25, p < 0.001, η 2 p = 0.09) although no significant two-way interactions (arousal: F1, 135 = 0.72, p = 0.487, η 2 p = 0.011, intensity: F1, 135 = 1.24, p = 0.292, η 2 p = 0.018). An exploratory post hoc analysis showed that both emotional arousal and intensity ratings for fear faces in the OT3 group were decreased on the 5 th day (arousal: p = 0.01 versus PLC, d = 0.55, p = 0.02 versus OT5, d = 0.47; intensity: p = 0.05 versus PLC, d = 0.42) but not on the first day (ps > 0.27) ( Fig.3A-B) . No significant main effects or interactions were found for valence ratings (ps > 0.12).
Right-amygdala seed-to-whole brain fMRI resting-state analysis by mixed-effect ANOVA revealed a main effect of treatment (OT3, OT5 and PLC) on amygdala functional coupling with vmPFC (peak MNI x = -3, y =53, z = -19, F2, 135 = 16.55, pFWE = 0.001, k = 88) before subjects underwent the face paradigm, whereas no brain regions showed a significant time point x treatment interaction. Post-hoc analyses demonstrated that right amygdala intrinsic connectivity with the vmPFC was stronger in both the OT3 (k = 74, pFWE = 0.014, x = -3, y = 53, z = -19) and OT5 groups (k = 127, pFWE = 0.001, x = -3, y = 53, z = -19) relative to PLC. Subsequent confirmatory analyses of resting state functional connectivity in this pathway acquired after the face task paradigm confirmed a significant main effect of treatment (F2, 135 = 7.081, p = 0.001, η 2 p = 0.095). Post hoc comparisons showed both groups exhibited increased connectivity in this pathway after a single OT dose on the 1 st day (OT3, p = 0.001, d = 0.71; OT5, p = 0.063, d = 0.40; relative to PLC) and after repeated doses on the 5 th day (OT3 p = 0.047, d = 0.46; OT5, p = 0.001, d = 0.69; relative to PLC). The OT3 and OT5 groups did not differ significantly on the 1 st (p = 0.140) or 5 th (p = 0.208) day ( Fig. 4B) .
Although not included in our primary outcome measures the (calcarine) visual cortex showed the same reduced responsivity to daily OT as the amygdala, but the superior frontal gyrus did not (see SI). Voxel based morphometry analysis revealed no evidence for acute or repeated dose effects of OT on gray matter volume (see SI).
Associations with OXTR genotype and trait autism
The number of G-carriers and G-non-carriers of rs53576 as well as A-carriers and A-non-carriers of rs2254298 did not differ between the three groups and both SNPs satisfied the Hardy Weinberg Equilibrium (see Tables S2 and S3 ). With Bonferroni-correction for the multiple SNPs and alleles (i.e. 2 x 2 = 4), p < 0.0125 was considered significant. For amygdala responses there was a significant treatment x genotype interaction for rs53576 (F2, 105 = 6.01, p = 0.003, η 2 p = 0.10) but not for rs2254298 (F2, 105= 1.48, p = 0.232, η 2 p = 0.03). For rs53576, OT-induced amygdala suppression on day 1 was only significant in G-non-carriers (p < 0.001, d =1.00) and also on the 5 th day in the OT3 group (p < 0.001, d =1.41). An exploratory post hoc analysis for rs2254298 revealed that OT-induced suppression on the 1 st day across treatment groups was only significant in A-carriers (p = 0.001, d = 0.91) and also on the 5 th day in the OT3 group (p = 0.004, d =0.81) (see Fig. 5 ). Similar patterns of genotype association were found for the visual cortex but not superior frontal gyrus responses to fear faces (see SI). For both emotional arousal and intensity ratings there was a significant treatment x genotype interaction for rs2254298 (arousal: F2, 105= 7.82, p = 0.001, η 2 p = 0.13, intensity: F2, 105= 6.25, p = 0.003, η 2 p = 0.11). Post-hoc analyses revealed no differences on the 1 st day between OT and PLC groups all ps>0.10) but on the 5 th day the reductions in arousal and intensity ratings in the OT3 group were only significant in A-carriers (arousal: p < 0.001, d =1.14, intensity: p < 0.001, d =1.19) (Fig. 5) . No associations with trait autism scores (AQ) achieved significance.
Since comparable patterns of OT effects were observed on pre-and post-task resting state data right amygdala-vmPFC functional connectivity values were pooled to increase power (Fig. 4B) . No significant main or interaction effects of genotype for either SNP (rs 2254298 all ps > 0.262; rs53576 all ps > 0.396) were found although a negative association between total AQ scores and strength of functional connectivity was observed in the PLC group on the 1 st day (r = -0.32, p = 0.029) which was significantly reduced by OT in both groups on the 1 st day (OT3, r = 0.21 p = 0.170;
Fisher's z = 2.51, p = 0.012; OT5, r = 0.10, p = 0.500; z = 2.07, p = 0.038). The same effect was also seen on the 5 th day (PLC: r = -0.33 p = 0.025; OT3, r = -0.03 p = 0.837; z = 1.41, p = 0.16; OT5 group, r = 0.10 p = 0.475; z = 2.11, p = 0.035) (Figs.
4C-4D).
Discussion
Overall, our findings firstly validate the use of OT-reductions in amygdala responses to fear-faces and associated emotional intensity ratings together with increased resting state functional connectivity between the amygdala and vmPFC as robust markers for its effects. Intriguingly, these task-dependent and resting-state effects of OT show a markedly different sensitivity to repeated intranasal doses and OXTR genotype, although our results indicate that to achieve both maximal task and resting-state changes an optimal protocol using the standard 24IU dose may be to administer it every other day rather than daily. Indeed, amygdala and particularly behavioral anxiolytic responses to fearful faces were more pronounced after 5 days when OT was administered every other day, and even with the resting-state and superior frontal gyrus changes there was no advantage of giving OT daily as opposed to every other day.
Our findings are therefore consistent with those in animal models demonstrating OXTR desensitization following repeated doses of OT in some brain regions [12] and that chronic administration can reduce brain OXTR expression [15] and altered patterns of neurochemical release [16] . While we did not use the twice daily administration protocol employed to date in clinical trials we anticipate that this would likely produce even stronger receptor-desensitization effects. However, at this point we have only demonstrated repeated-dose effects on amygdala and visual cortex fear reactivity in this respect and those on other behavioral and neural domains remain to be established. Nevertheless, the amygdala is one of the main targets for functional effects of OT and is dysfunctional in many psychiatric disorders including social impairments and anxiety [36, 37] . Interestingly, chronic doses of OT in rodents fail to produce anxiolytic effects normally seen with single doses [15] and thus daily repeated doses in humans might also reduce its efficacy in decreasing social anxiety.
Our second major finding is that the effects of OT on reducing amygdala and visual cortex responses to fear faces are highly dependent on OXTR genotype. Only G-non-carriers of rs53576 (i.e. AA) and A-carriers of rs2254298 (i.e. AA and AG) and AA homozygotes for rs53576 and A+ carriers of rs2254298 were significantly responsive to OT. A-carriers of both SNPs have frequently, although not universally, been associated with social dysfunction in autism as well as empathy [17, 18] . A recent haplotype-based analysis of OXTR SNPs including rs53576 and rs2254298 also indicated that individually they have some association with sensitivity to OT-effects on face recognition [22] . Again, while the current study clearly indicates that OT modulation of amygdala and visual cortex responses to fear are strongly associated with the AA genotype (Cohen's ds from 0.81-1.41), its effects on other regions and behaviors might show a different association. Limitations to the findings are that subject numbers are still relatively low for establishing robust genetic associations and that the AA allele of rs53576 occurs more frequently in Asian compared with Caucasian populations [38] . Also rs53576 exhibits some sex-dependent differences in social cooperation effects of OT [21] and our current study focused only on males to avoid potential menstrual cycle effect issues.
Interestingly, task-related and intrinsic network changes produced by OT showed a strikingly different sensitivity to repeated doses and OXTR genotype and only the resting state changes were actually significantly associated with trait autism.
However, importantly there was no advantage of giving OT daily as opposed to every other day. Intrinsic networks may be less influenced by repeated doses of OT or OXTR genotype than those activated by tasks, although this remains to be more fully established. Future studies should measure differential OT effects on both task-related and intrinsic networks.
In conclusion, the current study provides strong evidence for an important influence of dose frequency and receptor genotype on the neural and behavioral actions of intranasal OT in response to fear faces in healthy human subjects. Dose frequency should therefore be taken into consideration when designing future clinical trials using repeated doses of OT as an intervention in psychiatric disorders, particularly in relation to reducing social anxiety. 
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